Latest Posts › Mergers

Share:

DAMITT Q1 2025: Slow Start to Merger Enforcement Amid Leadership Transitions in U.S. and EU

Only three significant U.S. merger investigations concluded in Q1 2025 during the presidential transition. All three resulted in a complaint seeking to block the merger, including two under the new Trump administration....more

DAMITT 2024 Annual Report: Merger Enforcement at Low Tide on Both Sides of the Atlantic, but 2025 may Bring a Sea Change

United States - 2024 ended with 17 concluded significant merger investigations, the second-lowest total in DAMITT’s 14-year history, behind only the record-low 12 concluded in 2023 also under the Biden administration....more

Dechert Provides Comments to the U.S. Antitrust Agencies on Proposed Changes to Hart-Scott-Rodino Premerger Filings

Dechert’s antitrust group submitted comments today to U.S. antitrust agencies on their proposed top-to-bottom overhaul of premerger antitrust filings made under the Hart-Scott-Rodino (HSR) Act. The Federal Trade Commission...more

FTC Pharma Merger Enforcement is Robust But Needs Greater Clarity and Consistency

Key takeaways - The Federal Trade Commission (FTC) and antitrust agencies in North America and Europe have launched a Task Force to evaluate their current approach to pharmaceutical mergers reviews. The Task Force has sought...more

Big (But Not Bad) Data and Merger Efficiencies

“Big data” has become one of the hottest subjects for antitrust enforcers around the globe. There is concern that large tech companies are amassing vast amounts of data and will use that data to entrench their dominant...more

The FTC Requires Largest-Ever Generic Drug Divestiture

The U.S. Federal Trade Commission (FTC) recently announced a settlement resolving its competitive concerns over the merger of two leading generic drug manufacturers – Teva and Allergan. In July 2015, Teva agreed to acquire...more

7 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide